Compare IBP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | NUVL |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.1B |
| IPO Year | 2014 | 2021 |
| Metric | IBP | NUVL |
|---|---|---|
| Price | $286.27 | $98.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $276.00 | $135.33 |
| AVG Volume (30 Days) | 323.4K | ★ 437.9K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 9.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | N/A |
| Revenue This Year | $2.46 | N/A |
| Revenue Next Year | $4.53 | $1,064.25 |
| P/E Ratio | $29.66 | ★ N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $150.83 | $55.54 |
| 52 Week High | $349.00 | $113.02 |
| Indicator | IBP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 44.15 |
| Support Level | $254.83 | $98.37 |
| Resistance Level | $293.53 | $107.13 |
| Average True Range (ATR) | 13.62 | 3.66 |
| MACD | -4.44 | -0.27 |
| Stochastic Oscillator | 24.63 | 29.17 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.